LinkedInFacebookXYouTube

M&A Insights and Solutions

Dive into our extensive collection of resources and expert insights on mergers and acquisitions (M&A) within the BioPharma industry. Our content includes in-depth analyses such as the Quality of Clinical Data Report, Pipeline Intelligence, and Vanguard and Big Pharma dynamics. Explore posts on the challenges and benefits of Big Pharma M&As, strategies for enhancing R&D due diligence, and our eyesON Big Pharma M&As visualizer. Additionally, access our recorded webinars and presentations for a comprehensive understanding of maximizing deal value and minimizing risks in your M&A endeavors.

Jun 2024

BioPharma M&A Efficiency: Quality of Clinical Data Report

By |2024-06-14T17:03:55+02:00June 10, 2024|Blog, M&A Insights and Solutions, News|Comments Off on BioPharma M&A Efficiency: Quality of Clinical Data Report

Enhance your clinical due diligence in pharma M&A with our Quality of Clinical Data Report. Watch our webinar recording and explore mindsON RBQM workshops for practical RBQM roll-out advice.

Read More
Sep 2023

Pipeline Intelligence & M&A in the Modern Pharma Landscape

By |2024-06-07T14:29:11+02:00September 5, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Pipeline Intelligence & M&A in the Modern Pharma Landscape

In a fast-changing pharma landscape, our MyRBQM® Portal transforms clinical trial and pipeline oversight and aids in M&A due diligence, offering a strategic edge in compliance and growth.

Read More
Sep 2023

Vanguard vs. Big Pharma: Research Focus & Recruitment

By |2024-06-07T14:29:51+02:00September 4, 2023|M&A Insights and Solutions, News|Comments Off on Vanguard vs. Big Pharma: Research Focus & Recruitment

Explore how Vanguard companies, innovative small pharma entities, differ in research focus and recruitment dynamics from larger Pharma.

Read More
May 2023

Big Pharma M&As: Is It Worth the Trouble?

By |2024-06-07T14:30:31+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Big Pharma M&As: Is It Worth the Trouble?

Big Pharma M&As: A Worthwhile Challenge? Navigating the complex landscape of M&As in the pharmaceutical industry comes with unique objectives and potential benefits. But do these transactions truly drive shareholder value for the acquiring firm?

Read More
May 2023

Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

By |2024-06-07T15:19:19+02:00May 10, 2023|Blog, M&A Insights and Solutions, News|Comments Off on Enhancing R&D Due Diligence in Pharma M&As: The Role of MyRBQM Portal

Navigate your M&A journey confidently with Cyntegrity's MyRBQM Portal. Aspiring to hit your targets within 6-12 months? Discover how we can make it possible in R&D due diligence.

Read More
Apr 2023

eyesON | Big Pharma M&As: Clinical Trials Data Visualization

By |2024-06-07T15:20:19+02:00April 25, 2023|Interactive Data Visualizations, M&A Insights and Solutions, News|Comments Off on eyesON | Big Pharma M&As: Clinical Trials Data Visualization

Users can explore the impact of M&As on pharma companies, by examining how it affects their number of ran clinical trials, R&D spending, and share prices.

Read More
Go to Top